A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

May 20, 2026 updated by: Eli Lilly and Company

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 317-615-4559
  • Email: LillyTrials@Lilly.com

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1119ACN
        • Recruiting
        • CIPREC
        • Principal Investigator:
          • Angela Romero Zarante
        • Contact:
          • Phone Number: 5491165496764
      • Buenos Aires, Argentina, C1128AAF
        • Recruiting
        • Mautalen Salud e Investigación
        • Contact:
          • Phone Number: 541145143400
        • Principal Investigator:
          • Jose Fretes
      • Buenos Aires, Argentina, C1425AGC
        • Recruiting
        • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
        • Principal Investigator:
          • Antonela Mainardi
        • Contact:
          • Phone Number: 01148019001
      • Buenos Aires, Argentina, 1424
        • Recruiting
        • Cicemo Srl
        • Contact:
          • Phone Number: 5491157417654
        • Principal Investigator:
          • Pablo Costanzo
      • CABA, Argentina, 1204
        • Recruiting
        • Instituto Centenario
        • Principal Investigator:
          • SUSANA SALZBERG
        • Contact:
          • Phone Number: 5491121559419
      • Rosario, Argentina, 2000
        • Recruiting
        • Instituto Médico Catamarca IMEC
        • Contact:
          • Phone Number: 3416176661
        • Principal Investigator:
          • Natacha Maldonado
  • United States
    • Arizona
      • Tucson, Arizona, United States, 85712
        • Active, not recruiting
        • Tucson Clinical Research Institute
    • California
      • Spring Valley, California, United States, 91978
        • Active, not recruiting
        • Encompass Clinical Research
      • Tustin, California, United States, 92780
        • Recruiting
        • University Clinical Investigators, Inc.
        • Contact:
          • Phone Number: 714-734-7944
        • Principal Investigator:
          • Joanna Van
    • Florida
      • Clearwater, Florida, United States, 33761
        • Recruiting
        • Tampa Bay Medical Research
        • Contact:
          • Phone Number: 727-724-3316
        • Principal Investigator:
          • Sureka Bollepalli
      • Hollywood, Florida, United States, 33024
        • Active, not recruiting
        • Encore Medical Research
      • Lakeland, Florida, United States, 33805
        • Completed
        • Clinical Research of Central Florida
      • Weston, Florida, United States, 33331
        • Recruiting
        • Encore Medical Research - Weston
        • Principal Investigator:
          • Sandro Bacchelli
        • Contact:
          • Phone Number: 954-777-8827
    • Iowa
      • West Des Moines, Iowa, United States, 50266
        • Active, not recruiting
        • Iowa Diabetes and Endocrinology Research Center
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Completed
        • Washington University School of Medicine
    • North Carolina
      • Wilmington, North Carolina, United States, 28401
        • Recruiting
        • Accellacare - Wilmington
        • Principal Investigator:
          • John Parker
        • Contact:
          • Phone Number: 910-799-5500
    • Oklahoma
      • Norman, Oklahoma, United States, 73069
        • Completed
        • AMR Clinical
    • South Carolina
      • Greenville, South Carolina, United States, 29607
        • Completed
        • Tribe Clinical Research, LLC
    • Tennessee
      • Bristol, Tennessee, United States, 37620
        • Recruiting
        • Holston Medical Group
        • Contact:
          • Phone Number: 423-990-2478
        • Principal Investigator:
          • Rick Whiles
    • Texas
      • Austin, Texas, United States, 78749
        • Active, not recruiting
        • Texas Diabetes & Endocrinology, P.A.
      • Dallas, Texas, United States, 75230
        • Active, not recruiting
        • Velocity Clinical Research, Dallas
      • Houston, Texas, United States, 77040
        • Recruiting
        • Juno Research
        • Contact:
          • Phone Number: 713-779-5494
        • Principal Investigator:
          • Damaris Vega
      • Mesquite, Texas, United States, 75149
        • Completed
        • Southern Endocrinology Associates
      • Shavano Park, Texas, United States, 78231
        • Completed
        • Consano Clinical Research, LLC
      • Weslaco, Texas, United States, 78596
        • Recruiting
        • Texas Valley Clinical Research
        • Principal Investigator:
          • Eduardo Luna
        • Contact:
          • Phone Number: 956-431-8090
    • Utah
      • St. George, Utah, United States, 84790
        • Recruiting
        • Chrysalis Clinical Research
        • Contact:
          • Phone Number: 435-656-1704
        • Principal Investigator:
          • Joseph Woolley

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Have type 2 diabetes
  • Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
  • Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
  • Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Exclusion Criteria:

  • Have type 1 diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: LY3938577
Participants will receive LY3938577 subcutaneously (SC)
Drug: LY3938577
Administered SC
Active Comparator: Degludec
Participants will receive degludec SC
Drug: Degludec
Administered SC

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)
Time Frame: Baseline through Week 20
Baseline through Week 20

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Superiority Analysis)
Time Frame: Baseline through Week 20
Baseline through Week 20
Change from Baseline in Hemoglobin A1c (HbA1c)
Time Frame: Baseline, Week 20
Baseline, Week 20
Pharmacokinetics (PK): Average Concentration of LY3938577
Time Frame: Baseline through Week 20
Baseline through Week 20

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Eli Lilly and Company

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 13, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 9, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 9, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 10, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 27409
  • J4P-MC-IYAC (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on LY3938577

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings